Form 4: Skye Bioscience CEO Punit Dhillon Reports Share Acquisition and Disposal
SEC Form 4 Filing
CEO of Skye Bioscience, Punit Dhillon, reports acquisition and disposal of common stock, including shares received from a pro rata distribution and shares held in a family trust.
Summary
- Punit Dhillon, CEO of Skye Bioscience, filed a Form 4 detailing changes in beneficial ownership.
- On August 26, 2024, Dhillon acquired 15,727 shares of common stock through a pro rata distribution to shareholders.
- On the same day, Dhillon disposed of 412,733 shares of common stock.
- Dhillon also indirectly owns 9,343 shares through a family trust where he serves as trustee.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 08/26/2024 | Date of transaction involving acquisition and disposal of common stock. |
| 08/27/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.